SEARCH:   Advanced

Blood, 15 June 2008, Vol. 111, No. 12, pp. 5509-5514. Prepublished online as a Blood First Edition Paper on April 29, 2008; DOI 10.1182/blood-2008-02-136374. This Article Full Text Full Text (PDF) Supplemental Figure All Versions of this Article: blood-2008-02-136374v1 111/12/5509    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Malumbres, R. Articles by Lossos, I. S. PubMed PubMed Citation Articles by Malumbres, R. Articles by Lossos, I. S. Related Collections Gene Expression Clinical Trials and Observations Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP Raquel Malumbres1, Jun Chen1, Rob Tibshirani2, Nathalie A. Johnson3, Laurie H. Sehn4, Yaso Natkunam5, Javier Briones6, Ranjana Advani7, Joseph M. Connors4, Gerald E. Byrne8, Ronald Levy7, Randy D. Gascoyne3,*, and Izidore S. Lossos1,* 1 Department of Medicine, Division of Hematology-Oncology and Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center, University of Miami, FL; 2 Department of Health Research and Policy, and Statistics, Stanford University, CA; 3 Department of Pathology, 4 Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC; 5 Department of Pathology, Stanford University School of Medicine, CA; 6 Department of Clinical Hematology, Hospital Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain; 7 Department of Medicine, Division of Oncology, Stanford University School of Medicine, CA; and 8 Department of Pathology, University of Miami, FL Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease characterized by variable clinical outcomes. Outcome prediction at the time of diagnosis is of paramount importance. Previously, we constructed a 6-gene model for outcome prediction of DLBCL patients treated with anthracycline-based chemotherapies. However, the standard therapy has evolved into rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Herein, we evaluated the predictive power of a paraffin-based 6-gene model in R-CHOP–treated DLBCL patients. RNA was successfully extracted from 132 formalin-fixed paraffin-embedded (FFPE) specimens. Expression of the 6 genes comprising the model was measured and the mortality predictor score was calculated for each patient. The mortality predictor score divided patients into low-risk (below median) and high-risk (above median) subgroups with significantly different overall survival (OS; P = .002) and progression-free survival (PFS; P = .038). The model also predicted OS and PFS when the mortality predictor score was considered as a continuous variable (P = .002 and .010, respectively) and was independent of the IPI for prediction of OS (P = .008). These findings demonstrate that the prognostic value of the 6-gene model remains significant in the era of R-CHOP treatment and that the model can be applied to routine FFPE tissue from initial diagnostic biopsies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020